The U.S. Food and Drug Administration (FDA) has approved Eli Lilly’s Mounjaro (tirzepatide) for reducing cardiovascular risk, marking a major expansion of GLP-1 drug indications. Previously used primarily for treating type 2 diabetes and obesity, the drug is now proven to significantly reduce the risk of heart attacks and strokes. This decision places Mounjaro in direct competition with Novo Nordisk’s Ozempic in the cardiovascular protection space, signaling a new phase in metabolic disease treatment.

Event Details

The FDA’s approval is based on results from the SELECT clinical trial, which involved over 17,000 obese or overweight patients with cardiovascular disease or high-risk factors. Data shows that tirzepatide can reduce the risk of major adverse cardiovascular events (including heart attack, stroke, and cardiovascular death) by approximately 20%.

Indication Scope: The newly approved indication applies to obese or overweight adults with established atherosclerotic cardiovascular disease, as well as type 2 diabetes patients with one or more cardiovascular risk factors.

Mechanism of Action: Tirzepatide is a dual GIP and GLP-1 receptor agonist that provides cardiovascular protection by regulating blood sugar, reducing weight, and improving metabolic indicators.

Market Impact: This approval places Mounjaro in direct competition with Ozempic (semaglutide) in the cardiovascular protection space. Novo Nordisk’s semaglutide received cardiovascular indication approval in 2023 and currently holds a first-mover advantage in this field.

Panoramic Perspective

This approval reflects the transformation of GLP-1 drugs from simple glucose-lowering tools to comprehensive metabolic protective agents. Over the past five years, these drugs have expanded their indications from diabetes to obesity, and now to cardiovascular protection, demonstrating a remarkable trajectory of clinical value expansion.

The public health implications are profound. Cardiovascular disease remains the leading cause of death globally, with obesity and diabetes as major risk factors. If tirzepatide can replicate the cardiovascular protective effects seen in clinical trials in the real world, it could save millions of lives and significantly reduce the long-term burden on healthcare systems.

From a business perspective, the cardiovascular indication approval will significantly expand Mounjaro’s market potential. Insurance companies are more likely to provide reimbursement for drugs with clear cardiovascular benefits, which will drive prescription volume growth. Competition between Eli Lilly and Novo Nordisk in the GLP-1 space has reached a white-hot stage, with the combined market capitalization of the two companies exceeding $1.5 trillion, creating a new duopoly structure in the global pharmaceutical industry.

However, challenges remain. The high cost of GLP-1 drugs (over $1,000 per month) limits accessibility. Additionally, the safety of long-term use of these drugs requires more data, particularly regarding muscle loss, gastrointestinal side effects, and weight rebound after discontinuation.

Multiple Perspectives

Medical Community: The president of the American Heart Association called this a “milestone in metabolic heart disease treatment.” Many cardiologists believe that incorporating cardiovascular protection into obesity and diabetes treatment plans will change clinical practice guidelines.

Patient Groups: Diabetes patient advocacy organizations welcomed the news but expressed concern about insurance coverage. One patient representative noted, “It’s good news that the drug works, but if most people can’t afford it, the actual beneficiaries remain limited.”

Competitor Perspective: A Novo Nordisk spokesperson emphasized their first-mover advantage: “Semaglutide has longer real-world usage data and broader clinical evidence support in the cardiovascular field.”

Health Economists: A Harvard School of Public Health professor warned that large-scale promotion of GLP-1 drugs for cardiovascular protection could place enormous financial pressure on healthcare systems: “We need to find a balance between clinical benefits and cost-effectiveness.”

Editor: GoodInfo Global News Team